Patents by Inventor Steven Fuhrmann

Steven Fuhrmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof
    Patent number: 10232003
    Abstract: The present invention relates to exogenous TAP inhibitor armed oncolytic viruses that replicate selectively in cancer cells, evade CD8+ cytolytic T-cells, and induce the immune system to recognize tumor cells. Preferred viruses of the invention have a heterologous gene that encodes a function that affects antigen presentation by inhibiting TAP. The viruses of the invention also comprise one or more heterologous genes encoding immunomodulatory polypeptides, prodrug converting enzymes, or matrix degrading enzymes. Compositions and therapeutic methods using the oncolytic viruses are also provided, including compositions and therapeutic methods for treating cancers, such as melanoma, head and neck cancer, ovarian cancer, breast cancer, glioblastoma, bladder cancer, prostate cancer, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, and renal cancer.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 19, 2019
    Assignee: BeneVir Biopharm, Inc.
    Inventors: Matthew Mulvey, Steven Fuhrmann, Ram Aiyar
  • EXOGENOUS TAP INHIBITOR ARMED ONCOLYTIC VIRUSES AND THERAPEUTIC USES THEREOF
    Publication number: 20170173092
    Abstract: The present invention relates to exogenous TAP inhibitor armed oncolytic viruses that replicate selectively in cancer cells, evade CD8+ cytolytic T-cells, and induce the immune system to recognize tumor cells. Preferred viruses of the invention have a heterologous gene that encodes a function that affects antigen presentation by inhibiting TAP. The viruses of the invention also comprise one or more heterologous genes encoding immunomodulatory polypeptides, prodrug converting enzymes, or matrix degrading enzymes. Compositions and therapeutic methods using the oncolytic viruses are also provided, including compositions and therapeutic methods for treating cancers, such as melanoma, head and neck cancer, ovarian cancer, breast cancer, glioblastoma, bladder cancer, prostate cancer, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, and renal cancer.
    Type: Application
    Filed: March 30, 2015
    Publication date: June 22, 2017
    Applicant: BeneVir Biopharm, Inc.
    Inventors: Matthew Mulvey, Steven Fuhrmann, Ram Aiyar